Specify a stock or a cryptocurrency in the search bar to get a summary
Bioventix
BVXPBioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom. Address: 7 Romans Business Park, Farnham, United Kingdom, GU9 7SX
Analytics
WallStreet Target Price
455 819.84 GBXP/E ratio
0.2437Dividend Yield
4.27 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures BVXP
Dividend Analytics BVXP
Dividend growth over 5 years
31 %Continuous growth
9 yearsPayout Ratio 5 years average
105 %Dividend History BVXP
Stock Valuation BVXP
Financials BVXP
Results | 2019 | Dynamics |